MARKEDSPLEIEAVTALE

DiaGenic ASA har inngått en markedspleieavtale med Argo Securities AS for selskapets aksjer som er notert på Oslo Børs. Formålet med avtalen er å øke likviditeten i selskapets aksjer. Avtalen er i overensstemmelse med de krav som Oslo Børs stiller for godkjennelse av likviditetsgarantist. Avtalen er gjeldene fra i dag, 24. mars 2009.

Kontaktperson:

Dr Med Erik Christensen, administrerende direktør
Telefon: +47 95939918
e-mail: erik.christensen@diagenic.com

Om oss

DiaGenic ASA is an innovative Norwegian life sciences company founded in 1998 and listed on the Oslo Stock Exchange. DiaGenic develops patient-friendly tests for the early diagnosis of devastating diseases where early intervention is crucial for successful treatment. DiaGenic’s patented method is based on identifying disease-specific gene signatures from easily available sample material such as blood. DiaGenic's strategy is to work with research and technology partners to develop a pipeline of assays for commercialisation by major diagnostics companies. Currently DiaGenic’s first two tests for the early detection of breast cancer and Alzheimer’s disease are on track to enter extensive clinical trials during 2007. The company has been awarded substantial development grants as part of the Norwegian Research Council’s FUGE programme.

Abonner